Last reviewed · How we verify
melanoma helper peptide vaccine
melanoma helper peptide vaccine is a Biologic drug developed by Craig L Slingluff, Jr. It is currently in Phase 2 development. Also known as: 6 melanoma helper peptides restricted by class II MHC molecules, restricted by, HLADR molecules,, 6 class II MHC-Restricted Melanoma-Associated Peptides.
At a glance
| Generic name | melanoma helper peptide vaccine |
|---|---|
| Also known as | 6 melanoma helper peptides restricted by class II MHC molecules, restricted by, HLADR molecules,, 6 class II MHC-Restricted Melanoma-Associated Peptides |
| Sponsor | Craig L Slingluff, Jr |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) (PHASE1, PHASE2)
- Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (PHASE1, PHASE2)
- A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (EARLY_PHASE1)
- Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma (PHASE1, PHASE2)
- Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab (PHASE1, PHASE2)
- Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma (PHASE2)
- Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma (PHASE1, PHASE2)
- A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- melanoma helper peptide vaccine CI brief — competitive landscape report
- melanoma helper peptide vaccine updates RSS · CI watch RSS
- Craig L Slingluff, Jr portfolio CI
Frequently asked questions about melanoma helper peptide vaccine
What is melanoma helper peptide vaccine?
melanoma helper peptide vaccine is a Biologic drug developed by Craig L Slingluff, Jr.
Who makes melanoma helper peptide vaccine?
melanoma helper peptide vaccine is developed by Craig L Slingluff, Jr (see full Craig L Slingluff, Jr pipeline at /company/craig-l-slingluff-jr).
Is melanoma helper peptide vaccine also known as anything else?
melanoma helper peptide vaccine is also known as 6 melanoma helper peptides restricted by class II MHC molecules, restricted by, HLADR molecules,, 6 class II MHC-Restricted Melanoma-Associated Peptides.
What development phase is melanoma helper peptide vaccine in?
melanoma helper peptide vaccine is in Phase 2.
Related
- Manufacturer: Craig L Slingluff, Jr — full pipeline
- Also known as: 6 melanoma helper peptides restricted by class II MHC molecules, restricted by, HLADR molecules,, 6 class II MHC-Restricted Melanoma-Associated Peptides